Lipoleiomyoma is a rare and easily recognized benign variant of uterine leiomyoma, composed of an intimate admixture of mature smooth muscle cells and adipocytes, often with the former element predominant, most commonly found in the uterine corpus (1-4).
(January 2000 -April 2013). Seventy patients showed 76 lipoleiomyomas in the Department of Pathology.
For routine histological analysis, we fixed resected specimens in 10% formalin, embedded them in paraffin and stained them with hematoxylin and eosin (H&E). Pathological examination of the specimens was performed in the same hospital in the Department of Pathology. A single pathologist (MA) reviewed and evaluated all the slides on a retrospective basis with a light microscope. Relevant clinical, pathological, and radiological information was obtained from the patient's files and record forms. In the follow-up, we reviewed medical records and communicated with the patients.
Histological and pathological information was collected, including the presence and degree of accompanying carcinoma, endometrial hyperplasia, endometrial polyp, endometriosis, adenomyosis, atypia of smooth muscle cells, atypia of adipocytes, necrosis, mitosis, lymphocytic infiltration, and tumor borders (circumscribed versus infiltrative). The presence and amount of adipocytes was graded using a three tier grading system as Grade 1: minimal, focal; Grade 2: minimal to moderate, multifocal; Grade 3: abundant, multifocal, evenly distributed.
The histological diagnosis used H&E stains. Immunohistochemical (IHC) staining was previously performed in many cases on fixed paraffin-embedded sections on a Dako Autostainer Link48 (Dako North America, Inc., California, USA). We performed immunohistochemical analysis on 4-mm thick, formalin-fixed, paraffin-embedded representative tissue sections from selected cases, using an indirect immunoperoxidase technique and using antibodies against desmin, vimentin, smooth muscle actin (SMA), S100, HMB-45, Ki-67, ER, and PR receptors (DAKO, Glostrup, Denmark). We used appropriate positive controls for each antibody. Table 1 summarizes the monoclonal antibodies used.
The study was carried out in accordance with the Declaration of Helsinki and approved by the institutional ethical committee.
Statistical analysis
Findings were analyzed using the statistical software SPSS for Windows, version 17 (SPSS, Chicago, IL, USA). With the Spearman correlation and chi-square analysis, we tested for correlations of lipoleiomyomas with various pathologic and clinical features, including age, carcinoma, endometrial hyperplasia, endometrial polyps, endometriosis, and adenomyosis. A p value of <0.05 was used to define a significant association.
RESULTS
From 2000 to 2013, the Pathology Department's files included 70 patients with 76 uterine lipoleiomyomas. During the same duration, 2600 uterine leiomyomas were seen, thus lipoleiomyoma of the uterus comprised 2.9% of all uterine leiomyomas at our institution.
The patients ranged in age from 34 to 77 years, with a mean age of 55.49 years, and with median age of 55.50 years. Fiftyeight patients (82.8%) were postmenopausal. None were pregnant. Most sought medical attention for symptomatic leiomyomas (pelvic pain, enlarged uterus, and/or dysmenorrhea). The others sought treatment of a gynecological neoplasm.
The patients underwent a variety of different surgical procedures: 62 (88.5%) underwent hysterectomy and bilateral salpingo-oophorectomy, while eight (11.4%) underwent myomectomy. The majority of lipoleiomyomas were in the uterine corpus (69 cases, 90.7%), but some were found in the cervix (5 cases, 6.5%). Another was retroperitoneal and one was located in the broad ligament (1.3%). Fifty-eight tumors affected the uterine corpus, and were intramural, two were submucosal, and nine were subserosal. Six patients (8.5%) had two nodules of lipoleiomyomas each. All others had solitary lipoleiomyomas.
The size of the lipoleiomyomas ranged from 0.5 to 55 cm in diameter, with a mean of 5.50 cm. All were nodular and sharply circumscribed. Some were firm and rubbery, while others were fibro-fatty, with pale to yellow irregular soft areas. In cases with considerable amounts of fat, the cut surface was yellow (Figure 1 ). Grade I (minimal and concentrated in only focal areas) adipocytes were seen in 35 (46.05%), grade II (moderate) in 3 (3.9%) and grade III (abundant, multifocal and evenly distributed throughout the tumor) in 38 (50%) lipoleiomyomas.
Lymphocytes massively infiltrated the lipoleiomyomas in six cases (7.8%). The tumors were otherwise typical of uterine leiomyomas. None displayed mitosis, cytologic atypia (in smooth muscle cells or adipocytes), immature lipoblasts, necrosis, calcification, or other degenerative changes. The tumors were sharply separated from the adjacent myometrium, with no infiltrative margins. In seven cases (9.2%), in addition to smooth muscle tissue and adipose tissue, angiomatous hyperplasia was also present. In all 70 patients, we found 12 cases (17.1%) of gynecologic malignancies; including eight endometrial (11.4%), three ovarian, (4.2%) and one breast (1.4%). In the patients with an endometrial malignancy, uterine lipoleiomyoma was an incidental diagnosis during surgery. In cases in which there was a malignancy, there was no gross or microscopic contiguity between the lipoleiomyoma and the malignancy. The present study recognized eight cases of diabetes mellitus and six cases of hypothyroidism. Table 2 summarizes the diagnoses other than lipoleiomyoma.
We found no significant correlation between amount of adipocytes and other clinical and pathological features, none between the proportion of lipomatous and leiomyomatous components and the size of tumor, and none between the amount and distribution of the lipomatous component and the age of the patients.
In the immunohistochemical investigation, we studied the expression of ER and PR receptors, Ki-67, SMA, HMB-45, desmin, vimentin in selected cases. The adipose tissue and smooth muscle elements were positive for vimentin, desmin, S100 protein, ER, PR, and Ki-67 (Figures 2 and 3) . The examined tumor markers (CEA, CA19-9, CA125) were normal.
There were no recurrences or deaths attributed to the lipoleiomyomas during a mean follow-up period ranging from one to eight years (mean, 4.5 years). Follow-up data are available for 62 patients (88.5%).
DISCUSSION
In the present study, 53 patients with lipoleiomyomas (75.7%) had different types of lesions associated with hyperestrogenic status such as adenomyosis, endometriosis, endometrial hyperplasia, polyps, complex atypical endometrial hyperplasia, and gynecologic carcinomas. We suggest estrogenic manifestations may be an important factor in the development of lipoleiomyomas.
Uterine lipoleiomyoma is a rare and specific type of leiomyoma with a considerable amount of adipocytes (1-3). The clinical features and histogenesis of this tumor continue to be uncertain. In most of our patients, lipoleiomyoma was incidentally found during surgery for other reasons. As observed in previous studies, lipoleiomyoma most commonly grows in the uterine corpus at the subserosal or intramural levels (1, 2, 6, 9); however, it has been reported at other sites, including the cervix (1, 3, 10-12) as well as in intraligamentary, peritoneal, and ovarian areas (1, 2, 13). Lipoleiomyoma represented 2.9% of all leiomyomas in our study; a slightly lower incidence (0.03% to 2.1%) has been reported in the literature (1, 2, 5, 9). This may be related to the extensive sampling of all leiomyomatous nodules. Many lipoleiomyomas ranged from 0.5 to 2 cm in the study. The clinical presentation of uterine lipoleiomyomas is non-specific, and these tumors generally occur in asymptomatic obese perimenopausal or menopausal women (1, 2, 6 ). The most common signs and symptoms are abnormal uterine bleeding, abdominal and/or pelvic pain, a palpable mass, urinary frequency, incontinence and a sensation of pressure similar to those of typical leiomyomas (1, 2). Although most leiomyomas tend to predominate in women of reproductive age, lipoleiomyomas are frequently seen in older women. The mean ages of the patients in the series of Wang et al. (1) and Aung et al. (2) were 53.9 and 59.9 years, respectively. Lipoleiomyomas may rarely be multiple, but often are single, with variations in size (14) . In our study, six patients had two nodules of lipoleiomyoma. More than two lipoleiomyomas have not been described in the literature. Lipoleiomyomas range from 0.5 to 55 cm in size, with a mean of 5.50 cm. Four were larger than 10 cm. The literature contains reports of large lipoleiomyomas (4, 6, 10, 11).
Several pathogenic mechanisms may underlie the presence of adipocytes within leiomyomas, including misplaced embryonic fat cells, metaplasia of muscle, or differentiation of connective tissue cells into fat cells, lipocytic differentiation of a specific primitive connective tissue cell, perivascular fat cells accompanying the blood vessels into the uterus, inclusion of fat cells in the uterine wall during surgery, or fatty infiltration or degeneration of connective tissue (5, 15) . Fukunaga suggests that at least some lipoleiomyomas result from lipomatous metaplasia of leiomyomas, a theory supported by immunohistochemical findings (14) . However, numerous immunohistochemical studies have indicated a complex histogenesis of lipoleiomyoma which might arise from multipotential undifferentiated mesenchymal cells (15) or from direct transformation of smooth muscle cells into adipocytes (16) . Aung et al. (2) and Terada show focal proliferation of adipocytes, labeled by Ki-67 staining, and further suggest that the adipocyte component is neoplastic rather than degenerative (10). Terada also showed the presence of ER and PR in the adipose element, and suggested the adipose component of lipoleiomyoma is specific fat tissue related to the female genital organs (10) . In our study, fat tissue was positive for Ki-67, desmin, vimentin, and ER and PR receptors, supporting the direct transformation of muscle cells into adipose cells that may originate from the transformation of a totipotent mesenchymal cell (3, 17) .
Uterine smooth muscle cells have divergent differentiation potential and may undergo many alterations, including differentiation toward adipocytes or skeletal muscle. We suggest that the histological structure and immunohistochemical profile suggest that the lipoleiomyomas probably result from a metaplasia of the smooth muscle cells more than a true neoplastic process. Many authors have performed cytogenetic studies of uterine lipoleiomyomas, and suggest that uterine lipoleiomyomas have a pathogenic origin similar to that of typical leiomyomas (7) . Cytogenetic studies might therefore clarify the origin of this tumor. In the literature, many authors provide evidence to support a hyperestrogenic state contributing to the development of lipoleiomyomas (10, 18, 19) . Lipoleiomyomas may also be associated with some metabolic disorders such as hyperlipidemia, hypothyroidism, and diabetes mellitus (4, 10). After menopausal changes, lipid metabolism may play a role in lipoleiomyoma development. Adipocyte differentiation in the myometrium has been observed under conditions such as toxemia during pregnancy (20) , so environmental factors in the uterus may play a role in adipocyte differentiation in lipoleiomyomas (18, 20) . The relationship between gynecologic malignancies, which may originate from the uterus, cervix, or ovaries, and coexistent lipoleiomyoma has been reported in only a few studies (1-3, 6, 21) . In two large studies, Aung et al. (2) 10 cases (20%) of patients with uterine lipoleiomyoma associated with gynecologic malignancies. In our 70 patients, we found 12 cases (17.1%) of gynecologic malignancies: eight endometrial, three ovarian, and one breast. In these patients, a concomitant gynecologic malignancy and estrogen-related lesions appeared to be common, presumably related to estrogenic stimulation in these patients. This observation suggests that finding adipocytes in an otherwise normal leiomyoma should lead to further detailed clinical and pathological evaluation to search for the presence of a coexistent gynecologic neoplasm. This was also a significant observation of the present study. However, further studies on larger populations are needed to establish any association with malignancy, estrogenic status or metabolic disorders. Recognition of this rare and benign tumor is of great importance, because it may be confused with other gynecologic maladies, including spindle cell lipoma, angiolipoma, angiomyolipoma, atypical lipoma, myelolipoma, myxoid mesenchymal tumors, pelvic fibromatosis, well-differentiated liposarcoma, carcinosarcoma (malignant mixed Müllerian tumor) with heterologous liposarcomatous differentiation, ovarian fatty tumors, and benign or malignant degeneration of ordinary leiomyomas (1, 2) . Lipoleiomyosarcomas arising in uterine lipoleiomyomas have also been reported (22, 23) . Intravenous lipoleiomyomatosis has been rarely reported (24) . One report of intravascular lipoleiomyomatosis shows extension of the tumor into the inferior vena cava, a potentially life-threatening effect. While lipoleiomyomas are considered benign, close patient follow-up is necessary.
Lipoleiomyomas, if asymptomatic, require no treatment and are clinically similar to leiomyomas, so it is essential to distinguish these tumors from other tumors that need surgical excision (1). Uterine lipoleiomyomas are often diagnosed preoperatively as uterine leiomyomas or mature ovarian teratomas (25) . Fat within a uterine mass can be diagnostic of lipoleiomyoma or pure lipoma. Although ultrasonography has been thought to be specific enough to allow for tissue description and to establish a precise preoperative diagnosis (26) , magnetic resonance imaging (MRI) or computed tomography (CT) can exclusively show the fat content within the tumor (27) . Therefore, in combination with sonography, CT and MRI may assist in the preoperative diagnosis of lipoleiomyomas (1, 9, 16, 25, 26) . However; differentiation cannot be made on the basis of imaging findings alone, and histopathological evaluation must be performed to distinguish lesions in the differential diagnosis of lipoleiomyoma (9, 21) .
In conclusion, uterine lipoleiomyomas are benign uterine lesions that, in the present study, accounted for 2.9% of benign uterine leiomyomas. We conclude that uterine lipoleiomyomas represent a variant of leiomyoma with adipocyte differentiation rather than a degenerative or neoplastic change in ordinary leiomyoma. Patients with lipoleiomyomas have many estrogen-related conditions including endometriosis, adenomyosis, endometrial hyperplasia, polyps, and gynecologic malignancies. In this study, based on the follow-up information, lipoleiomyomas showed a favorable outcome. However, the pathogenesis and clinical significance of these rare neoplasms remain to be clarified. 
